Meriofert

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for subcutaneous use. It stimulates ovarian follicular development and ovulation in women with infertility due to anovulation, controlled ovarian stimulation for assisted reproductive technology, and hypogonadotropic hypogonadism.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics, and pharmacies worldwide, ensuring quality and regulatory compliance.

Meriofert is a gonadotropin used in reproductive medicine to stimulate ovarian function.

Infertility due to anovulation: Facilitates follicle growth and ovulation to improve chances of conception. Controlled ovarian stimulation for assisted reproductive technology: Enables synchronized follicle development for egg retrieval. Hypogonadotropic hypogonadism: Replaces deficient endogenous gonadotropins to restore normal ovarian activity.

Common Side Effects: - Injection site pain or erythema - Mild abdominal discomfort - Headache - Nausea - Transient ovarian hyperstimulation (mild) - Fluid retention

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe) - Multiple pregnancy - Thromboembolic events - Severe allergic reactions (anaphylaxis) - Ovarian cyst formation - Acute abdominal pain requiring medical attention

Precautions should be observed when using Meriofert to ensure patient safety. - Pregnancy testing: Confirm non‑pregnant status before initiating therapy. - Monitor ovarian response: Use ultrasound and estradiol measurements to adjust dosing. - Avoid in uncontrolled thyroid disease: Thyroid dysfunction can alter treatment outcomes. - Caution with existing ovarian cysts: May increase risk of complications. - Assess for hypersensitivity: Discontinue if severe allergic reaction occurs. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions require careful management.

Major Interactions (Avoid): - GnRH agonists: May amplify ovarian response leading to severe hyperstimulation. - Concurrent use of other gonadotropins: Additive effect can cause overstimulation.

Moderate Interactions (Monitor Closely): - Oral contraceptives: May blunt ovarian response, requiring dose adjustment. - Anticoagulants: Increased risk of bleeding at injection sites. - Thyroid hormone therapy: May affect overall hormonal balance and response.